Abivax Enrolls First Patient In ENHANCE-CD, Phase 2b Trial Of Obefazimod In Crohn's Disease
Portfolio Pulse from Benzinga Newsdesk
Abivax has enrolled the first patient in its Phase 2b trial, ENHANCE-CD, for the drug Obefazimod, aimed at treating Crohn's Disease.
October 03, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abivax has initiated the ENHANCE-CD Phase 2b trial for Obefazimod, targeting Crohn's Disease, marking a significant step in its clinical development.
The enrollment of the first patient in a Phase 2b trial is a critical milestone in drug development, indicating progress in Abivax's clinical pipeline. This could positively influence investor sentiment and potentially lead to a short-term increase in ABVX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100